Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0585 • ACR Convergence 2021
Predictors of Health-Related Quality of Life in Rheumatoid Arthritis Patients
Nejat Hassen¹, Yufei Zheng², Hui Xie², Karim Khan³, Jacek Kopec⁴ and Diane Lacaille², ¹University of British Columbia, Arthritis Research Canada, Richmond, BC, Canada, ²Arthritis Research Canada, Richmond, BC, Canada, ³University of British Columbia, Vancouver, BC, Canada, ⁴University of British Columbia, Richmond, BC, Canada
Background/Purpose: Health-related quality of life (HRQoL) is lower in rheumatoid arthritis (RA) patients compared to the general population, yet a comprehensive study evaluating predictors and…
Abstract Number: 0637 • ACR Convergence 2021
Assessing the Rates of Cervical Cancer Screening in Women with Systemic Lupus Erythematosus and Rheumatoid Arthritis
Tara Skorupa¹, Sonia Khatter², Alana Freifeld¹ and Elena Weinstein³, ¹University of Colorado, Denver, CO, ²University of Colorado, Aurora, CO, ³University of Colorado, Englewood, CO
Background/Purpose: Prior studies have described increased incidence of cervical dysplasia and cervical cancer in women with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), suggesting…
Abstract Number: 0791 • ACR Convergence 2021
Most Rheumatoid Arthritis (RA) Patients from Routine Care Reported in 2008-2021 Have Improved Outcomes vs Earlier Eras, but Most Remain in Moderate/high Disease Activity Rather Than Low Activity/remission: Are New Strategies for Earlier Treatment Needed in Addition to New Agents?
Juan Schmukler¹, Kyle Schroeder² and Theodore Pincus², ¹Mount Sinai Hospital - Rheumatology, Chicago, IL, ²Rush University Medical Center, Chicago, IL
Background/Purpose: Treatment of rheumatoid arthritis (RA) has been advanced considerably by biological agents with capacity for stringent control of inflammation. A “treat-to-target” directive toward remission…
Abstract Number: 0807 • ACR Convergence 2021
Baseline Coping Strategies as Predictors of Outcomes in Patients with Early-onset Rheumatoid Arthritis (RA)
Zafer Akman¹, Gilles Boire², Nathalie Carrier³, Sophie Roux⁴, Ariel Masetto², Artur deBrum Fernandes⁵, Patrick Liang², Patricia L Dobkin⁶ and Allard-Chamard Hugues⁷, ¹Istanbul University Cerrahpasa, İstanbul, Turkey, ²Universite de Sherbrooke, Sherbrooke, QC, Canada, ³CIUSSS de l'Estrie - CHUS, Sherbrooke, QC, Canada, ⁴Université de Sherbrooke, Sherbrooke, QC, Canada, ⁵Universite De Sherbrooke, Fleurimont, QC, Canada, ⁶McGill University, Montréal, QC, Canada, ⁷Universit de Sherbrooke, Sherbrooke, QC, Canada
Background/Purpose: Patients recently diagnosed with RA employ various coping strategies. We aimed to describe these strategies over time and determine if specific strategies impacted patient…
Abstract Number: 0826 • ACR Convergence 2021
Diagnosis, Treatment and Utilization Changes in Rheumatoid Arthritis Patients Before and During COVID-19
Miao Wang¹, Sylvie Lardeux², Elisea Avalos-Reyes³, Michele Hamburger⁴ and Kjel Johnson⁵, ¹CVS Health, New York, NY, ²CVS Health, Wellesley, MA, ³CVS Health, Irving, TX, ⁴Frances Hamburger Institute, Hauppauge, NY, ⁵CVS Health, Lincoln, RI
Background/Purpose: During the COVID-19 pandemic, individuals were encouraged to shelter in place, specifically those considered high risk for COVID-19. Rheumatoid arthritis (RA) patients are known…
Abstract Number: 0842 • ACR Convergence 2021
What Is the Success Rate in Clinical Trials of Discontinuation Glucocorticoids After Their Use as Bridging Therapy – a Systematic Literature Review
Lotte van Ouwerkerk¹, Isabell Nevins¹, Patrick Verschueren², Josef Smolen³, Robert Landewé⁴, Johannes Bijlsma⁵, Andreas Kerschbaumer³, Tom WJ Huizinga¹, Rene Westhovens⁶, Cornelia F. Allaart¹ and Sytske Anne Bergstra¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²University Hospitals Leuven - KULeuven, Leuven, Belgium, ³Medical University of Vienna, Vienna, Austria, ⁴Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam, Netherlands; Zuyderland MC, Heerlen, Netherlands, ⁵Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁶University Hospitals KU Leuven, Maaseik, Belgium
Background/Purpose: Short-term glucocorticoid (GC) bridging therapy results in rapid suppression of disease activity during the initial treatment of rheumatoid arthritis (RA) patients with DMARDs. But…
Abstract Number: 0997 • ACR Convergence 2021
Citrullinated Vimentin Induces Epigenetic Memory of the Innate Immune System
Katerina Laskari¹, Shweta Sabu², Oliver Distler³, Emmanuel Karouzakis² and Michel Neidhart², ¹Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ²Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ³Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich/University of Zurich, Zurich, Switzerland
Background/Purpose: During trained immunity, monocytes and macrophages undergo a functional and transcriptional reprogramming toward activation, which is induced by a priming stimulus and results in…
Abstract Number: 1076 • ACR Convergence 2021
Combining Fuzzy Logic with Time-Driven Activity Based Costing Within the Rheumatoid Arthritis Care Cycle: Insights from a Dutch Hospital
Fiona Koster¹, Deirisa Lopes Barreto², Marc Kok³ and Angelique Weel-Koenders¹, ¹Maasstad Hospital Rotterdam, Rotterdam, Netherlands, ²Maasstad Hospital Rotterdam, Rotterdam, ³Maasstad Hospital, Rotterdam, Netherlands
Background/Purpose: Transparency and management of healthcare costs is warranted for rheumatoid arthritis (RA) as the disease places a great economic burden on a patient and…
Abstract Number: 1202 • ACR Convergence 2021
Widespread but Not Regional Non-articular Pain Influences Patient and Rheumatologist Reported Change in Clinical Disease Activity Index Scores over Time – Implications for Using Patient Ratings in Telehealth – a Study from the Canadian Early Arthritis Cohort
Vivian Bykerk¹, Orit Schieir², Marie-France Valois³, Glen Hazlewood⁴, Gilles Boire⁵, Carol Hitchon⁶, Louis Bessette⁷, Diane Tin⁸, Edward Keystone⁹, Carter Thorne⁸, Janet Pope¹⁰ and Susan Bartlett³, ¹Hospital for Special Surgery, New York, NY, ²Canadian Early Arthritis Cohort Study, Montréal, QC, Canada, ³McGill University, Montréal, QC, Canada, ⁴University of Calgary, Calgary, AB, Canada, ⁵Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁶University of Manitoba, Winnipeg, MB, Canada, ⁷Centre de l'Ostoporose et de Rhumatologie de Qubec, Québec City, QC, Canada, ⁸Southlake Regional Health Centre, Newmarket, ON, Canada, ⁹Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ¹⁰University of Western Ontario, London, ON, Canada
Background/Purpose: During the COVID pandemic assessments of RA disease activity (DA) have relied on virtual assessments by patient report. It is unknown whether non-articular pain…
Abstract Number: 1218 • ACR Convergence 2021
Unsupervised Clustering Identifies Unique Subsets of Patients in a Racially and Ethnically Diverse Rheumatoid Arthritis Cohort
Gabriella Lui¹, Namrata Singh², James Andrews³, Jonathan Graf⁴ and Katherine Wysham⁵, ¹University of Washington Department of Bioengineering, Seattle, WA, ²University of Washington, Bellevue, WA, ³University of Washington, Seattle, WA, ⁴Ucsf, San Francisco, CA, ⁵VA Puget Sound/University of Washington, Seattle, WA
Background/Purpose: Single biomarkers have limited utility to date in guiding clinical care in RA. There is growing interest in applying machine learning algorithms to combine…
Abstract Number: 1234 • ACR Convergence 2021
Routine Assessment of Patient Index Data 3 (RAPID3) in Patients with Rheumatoid Arthritis Treated with Long-Term Upadacitinib Therapy
Martin Bergman¹, Maya Buch², Yoshiya Tanaka³, Gustavo Citera⁴, Sami Bahlas⁵, Ernest Wong⁶, Yanna Song⁷, Namita Tundia⁷, Jessica Suboticki⁷ and Vibeke Strand⁸, ¹Martin Jan Bergman, MD, Ridley Park, PA, ²University of Leeds, Leeds, United Kingdom, ³University of Occupational and Environmental Health, Kitakyushu, Japan, ⁴Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁵Medicine, King Abdulaziz University, Jeddah, Saudi Arabia, ⁶Rheumatology, Queen Alexandra Hospital, Portsmouth, United Kingdom, ⁷AbbVie Inc., North Chicago, IL, ⁸Stanford University School of Medicine, Portola Valley, CA
Background/Purpose: Routine Assessment of Patient Index Data 3 (RAPID3) is a pooled index of 3 patient-reported measures: patient global assessment, pain, and physical function. RAPID3…
Abstract Number: 1250 • ACR Convergence 2021
Abatacept and Other DMARDs Have Common Transcriptomic Effects on RA Synovial Tissue
Clément TRIAILLE¹, Tatiana SOKOLOVA¹, Gaëlle TILMAN¹, Laurent MERIC de BELLEFON², Christine GALANT³, Patrick DUREZ⁴, Bernard LAUWERYS⁵ and Nisha LIMAYE⁶, ¹Pôle de pathologies rhumatismales systémiques et inflammatoires, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, ²Service de Rhumatologie, Cliniques Universitaires Saint-Luc, Brussels, Belgium, ³Service d’Anatomie Pathologique, Cliniques Universitaires Saint-Luc, Brussels, Belgium, ⁴Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Brussels, Belgium, ⁵UCB Pharma, Brussels, Belgium, ⁶Genetics of Autoimmune Diseases and Cancer, de Duve Institute, Université catholique de Louvain, Brussels, Belgium
Background/Purpose: Our goal was to assess histological and transcriptomic effects of Abatacept (ABA) on RA synovium, and to compare them with previously published data obtained…
Abstract Number: 1450 • ACR Convergence 2021
Unsupervised Machine Learning Methods to Cluster Comorbidities in a Population-based Cohort of Patients with Rheumatoid Arthritis
Elizabeth Atkinson¹, Tina Gunderson¹, John Davis¹, Elena Myasoedova¹, Vanessa Kronzer¹, Caitrin Coffey¹ and Cynthia Crowson², ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Eyota, MN
Background/Purpose: Comorbidities are common in patients with rheumatoid arthritis (RA), and comorbidity patterns are of interest. We aimed to examine clusters of comorbidities and clusters…
Abstract Number: 1647 • ACR Convergence 2021
Interaction Effect of Systemic Inflammation and Dietary Protein Intake on Resting Energy Expenditure in Individuals with RA
Beatriz Hanaoka¹, Jing Zhao¹, Kristen Heitman¹, Fahad Khan¹, Guy Brock¹, Jeff Volek¹, Wael Jarjour¹ and Barbara Gower², ¹Ohio State University, Columbus, OH, ²University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: In rheumatoid cachexia (RC), high resting energy expenditure (REE) has been associated with loss of muscle mass driven by proinflammatory cytokines. The objectives of…
Abstract Number: 1665 • ACR Convergence 2021
Physical Activity Moderates Inflammatory Gene Expression in Rheumatoid Arthritis
Sarah Patterson¹, Shenghuan Sun², Dmitry Rychkov², Alexandra Tsitsiklis², Paula Hayakawa Serpa², Patricia Katz², Charles Langelier² and Marina Sirota², ¹University of California San Francisco, Pacifica, CA, ²University of California San Francisco, San Francisco, CA
Background/Purpose: Prior studies show an independent association between greater physical activity and lower inflammatory markers among adults in the general population, but the impact of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].